Get 40% Off
📈 Free Gift Friday: Instantly Copy Legendary Investors' PortfoliosCopy for Free

U.S. judge blocks Obamacare coverage mandate for some cancer screenings, PrEP

Published 03/30/2023, 10:43 AM
Updated 03/30/2023, 04:56 PM
© Reuters. FILE PHOTO: A sign on an insurance store advertises Obamacare in San Ysidro, San Diego, California, U.S., October 26, 2017. REUTERS/Mike Blake

By Brendan Pierson

(Reuters) - A federal judge in Texas on Thursday blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP), at no cost to patients.

U.S. District Judge Reed O'Connor in Fort Worth, Texas, previously found that the PrEP mandate violated a federal religious freedom law and that other no-cost preventive care mandates were based on recommendations by an illegally appointed task force.

The judge has now blocked the federal government from enforcing the mandates, a victory for conservative businesses and individuals that sued to challenge them in 2020. The ruling does not apply to preventive services, such as breast cancer screening, that were recommended before Obamacare, formally called the Affordable Care Act (ACA) was enacted in 2010.

White House spokesperson Karine Jean-Pierre said the Biden administration was reviewing the decision.

More than 150 million people were eligible for preventive care free of charge as of 2020 under the ACA, according to data from the U.S. Department of Health and Human Services. If O'Connor's ruling is not paused or overturned on appeal, insurers will be able to charge patients copays and deductibles for such services in new insurance plans.

AHIP, the health insurance industry's largest trade group, said there would be no immediate coverage interruptions.

"Every American deserves access to high-quality affordable coverage and healthcare, including affordable access to preventive care and services that help avoid illnesses and other health problems," said AHIP President Matt Eyles.

Major medical groups criticized the decision. American Medical Association President Jack Resneck called it "deeply flawed" and said that patients "will be subjected to needless illness and preventable deaths" as a result.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Lisa Lacasse, president of the American Cancer Society Cancer Action Network, said the ruling could have "huge implications" and make it more difficult to catch treatable cancers early.

"We cannot emphasize enough how important screenings are for early detection of cancer," she said.

The American College of Obstetricians and Gynecologists, in a statement, said: "Allowing personal or political bias to interfere with the practice of medicine will cause harm to our patients."

The legal challenge was brought by eight individuals and two businesses, all from Texas. They argued that the free PrEP requirement requires business owners and consumers to pay for services that "encourage homosexual behavior, prostitution, sexual promiscuity and intravenous drug use" despite their religious beliefs.

They also said that the advisory body that recommends what preventive care should be covered without cost, the Preventive Services Task Force, is illegal because its members are not directly appointed by the president, which they argue is required by the U.S. Constitution.

The task force's recommendations automatically become mandatory under the Affordable Care Act.

The conservative America First Legal Foundation is helping to represent the plaintiffs. The group was founded by Stephen Miller, who served as an adviser to Republican President Donald Trump.

O'Connor previously drew attention in 2018 for ruling the entire ACA, the signature achievement of Democratic then-President Barack Obama, was unconstitutional in a decision that was later overturned.

The PrEP drugs approved in the United States to prevent HIV infection, which can cause AIDS, are made by Gilead Sciences Inc (NASDAQ:GILD) and by ViiV Healthcare, a joint venture of GSK Plc, Pfizer Inc (NYSE:PFE) and Shionogi & Co Ltd.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

GSK and ViiV said in a statement that they were "concerned about any court order or policy that could negatively impact access to important health prevention services, including PrEP for HIV" and supported an appeal of O'Connor's order.

Latest comments

the democratic party will use the stupidity of Republican social policy in the next election cycle....this will label the Republican party and again, show to the American people, how dangerous the Republican Conservatives and there anti-American ideology have become...
More hostility to human well being from the right wing.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.